Bio-Techne and Lisen Imprinting Diagnostics form agreement

Bio-Techne signs strategic cooperation agreement with Lisen Imprinting Diagnostics

Register for free to listen to this article
Listen with Speechify
MINNEAPOLIS—Bio-Techne, a leading provider of high-quality consumables and instruments for the life science and molecular diagnostic markets, has entered into a strategic cooperation agreement in the precision medicine field with Lisen Imprinting Diagnostics Wuxi Co., Ltd., a high-tech technology company that develops diagnostic assays and services protected by multiple domestic and international patents.
Liwen Pei, managing director of Bio-Techne China, and Ning Zhou, CEO of Lisen, attended the meeting and signing ceremony. “I am excited about the collaboration with Lisen. The emerging molecular diagnostic market requires technical innovation as well as first-class quality reagents on which to build these novel tests,” said Pei.
Bio-Techne’s nucleotide RNAscope Assay product line is a next-generation RNA in situ hybridization platform in the emerging field of molecular pathology, which provides highly sensitive and reliable cell- and tissue- based tests for basic research, drug development, clinical biomarker validation and precision diagnostics development. Lisen Imprinting Diagnostics has independently developed several diagnostic methods for the oncology field that can detect changes in the early stages of tumor progression more accurately and intuitively, and provide precise personalized cancer diagnosis for patients.
“With innovation as the core driving force behind a growing business, Bio-Techne prides itself on providing high-quality, cutting edge genomic and proteomic solutions for our customers in both research and diagnostics,” noted Kim Kelderman, president, diagnostics and genomics segment, Bio-Techne. “In the area of genomics, we are thrilled to be collaborating with Lisen to advance the use of the RNAscope platform for China's precision diagnostic initiatives.”
The companies say that the cooperation between Bio-Techne and Lisen will be a strong partnership between two high tech-oriented companies. It will help the two sides to accelerate the development of molecular diagnostics in the Chinese market, and jointly promote the benefits of precision medicine as a result of more accurate diagnostics.
Zhou added, “As a high-tech diagnostic development company, Lisen is at the forefront of the rapidly growing medical industry. It is believed that this collaboration with Bio-Techne will give full play to the technological advantages of both parties and accelerate the development and market promotion of new diagnostic products.”

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue